- Tesamorelin Dosing, Honestly: Where 2 mg Comes From — and Why Many Protocols Run Lower The only tesamorelin dose ever tested in large trials is 2 mg daily — for one condition. The lower doses common in longevity practice are clinical judgment, not published evidence. Here's the honest read.
- Is BPC-157 Legal Now? What the FDA's Peptide Vote Actually Changed An FDA advisory committee voted to recommend six peptides — including BPC-157 — for the compounding pathway. That is not approval, and it changed nothing overnight. Here is the precise read.
- Peptide Therapy News 2026: What the FDA Compounding Vote Actually Changes An FDA advisory panel narrowly backed compounding six of seven reviewed peptides in July 2026 — over the objections of the agency's own scientists. Here's what that vote actually changes, and the honest timeline before anything reaches patients legally.
- How to Buy Peptides Legally Online: The Prescription Pathway in 2026 There is a legitimate way to get peptides online and a gray-market way. The legitimate path runs through a licensed clinician, a valid prescription, and a state-licensed pharmacy. Here's how to tell them apart.
- Compounded Peptides vs Research Chemicals: The Safety Difference Both arrive as a vial in the mail, but compounded peptides and research-chemical peptides are worlds apart on quality, legality, and who is accountable if something goes wrong.
- What Peptides Are Legal to Get Prescribed in 2026? The Current FDA Status The peptide legal picture shifted on July 23–24, 2026, when an FDA advisory committee recommended six of seven reviewed peptides — BPC-157 among them — for compounding, against FDA staff advice. Here is what is legal today, what changed, and what has not.
- Peptides for Preserving Muscle: What the Evidence Actually Supports No peptide replaces resistance training and protein for preserving muscle — but growth-hormone-axis peptides are a plausible supporting lever. Here's what the evidence honestly supports.
- Peptides for Visceral Fat: How They Fit With GLP-1 Weight-Loss Treatments Visceral fat is the metabolically dangerous depot. Tesamorelin selectively targets it; GLP-1 drugs cut total fat but risk muscle. Here's how the pieces honestly fit.
- What Is Tesamorelin? The GHRH Analog That Targets Visceral Fat, Explained Tesamorelin is a stabilized GHRH analog that prompts your own pituitary to release growth hormone — and, uniquely, selectively reduces visceral abdominal fat. Here's the honest read.
- Sermorelin vs Tesamorelin: What the Growth-Hormone-Axis Conversation Actually Says Sermorelin and tesamorelin are both GHRH analogs that ask your own pituitary to release growth hormone. Here's the honest comparison — potency, half-life, and what the human evidence actually supports.
- What Is Sermorelin? The Growth-Hormone-Axis Peptide, Explained Sermorelin is a GHRH (1-29) analog that signals your own pituitary to release growth hormone — preserving the body's own pulse and feedback. Here's the honest read.
